BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Drug Development

  Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA

  Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, provides an update on clinical results and timelines of the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA.

  February 24, 2022

   · 

  6 min read
• Business

  Devyser Diagnostics AB publishes Year End Report for the period January to December 2021

  Devyser’s sales were also strong in the fourth quarter 2021, as well as in the other quarters of the year.

  February 24, 2022

   · 

  5 min read
• Business

  AlzeCure Publishes its Year-End Report for 2021

  AlzeCure Pharma AB announced that its Year-end report for 2021 is now available on the company’s website.

  February 24, 2022

   · 

  5 min read
• Business

  Genus plc Reports Interim Results for the Six Months Ended 31 December 2021

  Genus, a leading global animal genetics company, announces its interim results for the six months ended 31 December 2021.

  February 24, 2022

   · 

  11 min read
• Business

  Elekta: Interim report, May-January 2021/22

  The demand for Elekta’s solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta’s strongest order backlog ever.

  February 24, 2022

   · 

  3 min read
• Business

  Invitation to Vimian’s Interim Report for the Fourth Quarter of 2021

  Vimian Group AB will publish its Interim Report for the period of January-December 2021 on Thursday, 10 March 2022, at 07.45.

  February 24, 2022

   · 

  2 min read
• Biotech Bay

  Endpoint Health Enters into Global Collaboration and Licensing Agreement with Grifols

  Endpoint Health, Inc. announced that the company has entered into a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines, under which Endpoint Health will receive exclusive rights to develop and commercialize Antithrombin III in sepsis.

  February 24, 2022

   · 

  5 min read
• Business

  Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

  Aerie Pharmaceuticals, Inc. today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022.

  February 24, 2022

   · 

  9 min read
• Sternal Closure Systems Market: The closure device segment is anticipated to expand at a rapid CAGR during the forecast period

  Sternal closure systems are intended for use in the stabilization as well as fixation of fractures of the anterior chest wall.

  February 24, 2022

   · 

  5 min read
• Medical Equipment Cooling Market: Rising prevalence of chronic diseases to drive the market

  Leading edge medical equipment often requires effective cooling. As heat loads continue to increase, many original equipment manufacturers are desperately looking for a more efficient cooling method.

  February 24, 2022

   · 

  5 min read